AA
IMVT icon

AlphaCentric Advisors’s Immunovant IMVT Stock Holding History

AlphaCentric Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-35,000
Closed -$998K – 249
2024
Q3 		$998K Sell
35,000
-1,500
-4% -$44.2K 0.74% 47
2024
Q2 		$964K Sell
36,500
-1,500
-4% -$42.7K 0.71% 50
2024
Q1 		$1.23M Hold
38,000
– – 0.74% 53
2023
Q4 		$1.6M Hold
38,000
– – 1.07% 31
2023
Q3 		$1.46M Buy
+38,000
New +$859K 0.83% 40
2021
Q1 		– Sell
-2,150
Closed -$99K – 216
2020
Q4 		$99K Hold
2,150
– – 0.04% 134
2020
Q3 		$76K Buy
2,150
+1,500
+231% +$45.1K 0.04% 80
2020
Q2 		$16K Buy
+650
New +$13.9K 0.01% 126

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AlphaCentric Advisors's IMVT Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Immunovant (IMVT) in Q4 2024, closing a stake of 35,000 shares — an estimated $998K sold.

AlphaCentric Advisors first reported a position in IMVT in Q2 2020 and held it in 8 quarters. The position peaked at $1.6M in Q4 2023. 186 funds tracked by Wall St. Rank hold IMVT as of Q4 2024.

  • AlphaCentric Advisors reported no remaining Immunovant position as of Q4 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 35,000 Immunovant shares in Q4 2024, an estimated $998K.
  • AlphaCentric Advisors first reported a position in Immunovant in Q2 2020 and held it in 8 quarters.
  • AlphaCentric Advisors's Immunovant position peaked at $1.6M in Q4 2023.
  • 186 funds tracked by Wall St. Rank held Immunovant as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.